WO2019245512A3 - Combinaison comprenant du fingolimod et au moins un agent anti-épileptique - Google Patents

Combinaison comprenant du fingolimod et au moins un agent anti-épileptique Download PDF

Info

Publication number
WO2019245512A3
WO2019245512A3 PCT/TR2019/050471 TR2019050471W WO2019245512A3 WO 2019245512 A3 WO2019245512 A3 WO 2019245512A3 TR 2019050471 W TR2019050471 W TR 2019050471W WO 2019245512 A3 WO2019245512 A3 WO 2019245512A3
Authority
WO
WIPO (PCT)
Prior art keywords
fingolimod
combination
epileptic agent
epileptic
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2019/050471
Other languages
English (en)
Other versions
WO2019245512A2 (fr
Inventor
Ali Turkyilmaz
Merve PEKER
Emine TUNCAY
Erkin Ozturk
Muge ULUSOY BOZYEL
Yavuz Dedeoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority to EP19822106.1A priority Critical patent/EP3810274A4/fr
Publication of WO2019245512A2 publication Critical patent/WO2019245512A2/fr
Publication of WO2019245512A3 publication Critical patent/WO2019245512A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une combinaison pharmaceutique comprenant du fingolimod ou un sel pharmaceutiquement acceptable de celui-ci et au moins un agent anti-épileptique.
PCT/TR2019/050471 2018-06-21 2019-06-19 Combinaison comprenant du fingolimod et au moins un agent anti-épileptique Ceased WO2019245512A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19822106.1A EP3810274A4 (fr) 2018-06-21 2019-06-19 Combinaison comprenant du fingolimod et au moins un agent anti-épileptique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201808815 2018-06-21
TR2018/08815 2018-06-21

Publications (2)

Publication Number Publication Date
WO2019245512A2 WO2019245512A2 (fr) 2019-12-26
WO2019245512A3 true WO2019245512A3 (fr) 2020-06-04

Family

ID=68983746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050471 Ceased WO2019245512A2 (fr) 2018-06-21 2019-06-19 Combinaison comprenant du fingolimod et au moins un agent anti-épileptique

Country Status (2)

Country Link
EP (1) EP3810274A4 (fr)
WO (1) WO2019245512A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140308244A1 (en) * 2011-08-08 2014-10-16 The Board Of Trustees Of The Leland Stanford Junior University Combination Therapy for Treatment of Inflammatory Demyelinating Disease
WO2018082814A1 (fr) * 2016-11-07 2018-05-11 Metriopharm Ag Utilisation de 5-amino-2,3-dihydro-1,4-phthalazinedione dans le traitement de la sclérose en plaques progressive chronique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20100371A1 (es) * 2008-10-31 2010-06-01 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de malaria cerebral
MX370184B (es) * 2013-05-13 2019-12-04 Synthon Bv Composición farmacéutica que comprende fingolimod.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140308244A1 (en) * 2011-08-08 2014-10-16 The Board Of Trustees Of The Leland Stanford Junior University Combination Therapy for Treatment of Inflammatory Demyelinating Disease
WO2018082814A1 (fr) * 2016-11-07 2018-05-11 Metriopharm Ag Utilisation de 5-amino-2,3-dihydro-1,4-phthalazinedione dans le traitement de la sclérose en plaques progressive chronique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
METIN, S. K. ET AL.: "The effect of pregabalin and methylcobalamin combination on the chronic postthoracotomy pain syndrome", THE ANNALS OF THORACIC SURGERY, vol. 103, no. 4, 2017, pages 1109 - 1113, XP029956788, DOI: 10.1016/j.athoracsur.2016.09.031 *
MIMENZA ALVARADO, A. ET AL.: "Clinical trial assessing the efficacy of gabapentin plus B complex (B 1/B 12) versus pregabalin for treating painful diabetic neuropathy", JOURNAL OF DIABETES RESEARCH, 2016, XP055711547 *

Also Published As

Publication number Publication date
EP3810274A4 (fr) 2022-03-16
WO2019245512A2 (fr) 2019-12-26
EP3810274A2 (fr) 2021-04-28

Similar Documents

Publication Publication Date Title
EP4527467A3 (fr) Formulations pharmaceutiques
EP4467195A3 (fr) Agents thérapeutiques pour maladies neurodégénératives
MX2017016802A (es) Formulaciones farmaceuticas.
PH12019501076A1 (en) Pharmaceutical formulations
MX2020012989A (es) Agente terapeutico para la fibrosis.
EP4342461A3 (fr) Compositions pharmaceutiques et utilisations contre des troubles du stockage lysosomal
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
WO2020009675A3 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine
EP4467138A3 (fr) Agents thérapeutiques pour maladies neurodégénératives
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
WO2020122838A3 (fr) Combinaison comprenant un agent de sclérose en plaques et au moins un agent anti-épileptique
PH12018501758A1 (en) Oritavancin formulations
WO2018094035A3 (fr) Conjugués ligand-ionophore
WO2019245512A3 (fr) Combinaison comprenant du fingolimod et au moins un agent anti-épileptique
WO2019209217A3 (fr) Formulations à libération modifiée de flurbiprofène
IL264538B2 (en) A new use of n,n-bis-2-mercaptoethyl isophthalamide
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
WO2020139238A3 (fr) Combinaisons pharmaceutiques comprenant du fingolimod et un spasmolytique
WO2019221684A3 (fr) Formulation de comprimé bicouche de fésotérodine
WO2020018053A3 (fr) Comprimé comprenant du dasatinib
WO2016108507A3 (fr) Comprimé composite destiné à une administration orale comprenant de la mélatonine et de la sertraline
TR201721065A2 (tr) Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19822106

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2019822106

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2019822106

Country of ref document: EP

Effective date: 20210121

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19822106

Country of ref document: EP

Kind code of ref document: A2